Background:
The number of women whose labours are induced is increasing with average rates in England in excess of 20%. A broad range of methods for induction are available, including pharmacological, mechanical and alternative interventions with considerable variation in effectiveness, safety and cost. Of the pharmacological interventions, the most commonly used are prostaglandins. However, even within this class, there are a variety of different prostaglandins, with a variety of modes of administration. The aim of this piece of work is to identify the most costeffective and safe prostaglandin for cervical ripening and labour induction in the NHS setting. The number of women whose labours are induced is increasing with average and alternative interventions with considerable variation in effectiveness, safety and cost.
Results:

Caesarean section
The complete network of eligible comparisons between treatments for caesarean section is shown in Figure 1 . 270 trials were available for inclusion. The nodes represent the number of patients randomized between each pair of treatments and the edges represent the number of studies comparing each pair of treatments.
Conclusion:
• Network meta-analysis provides a unique opportunity to rank the prostaglandin treatments in a coherent, methodologically robust manner, and allows comparisons to be made across outcomes to help guide clinicians and patients to make informed treatment choices.
• The NMA results show that misoprostol may be the best prostaglandin for labour induction as the titrated low dose oral solution appears to be the safest in terms of caesarean section risk, whilst vaginal misoprostol tablets (>50mcg) are the most effective in achieving vaginal delivery within 24 hours of induction. The cost-effectiveness analysis will combine the findings from the NMA with cost and utility data to identify the method of induction that is most cost-effective.
• These findings have important implications for national and international guidelines for induction of labour and future research in this area. 
Cost-effectiveness Analysis:
Objective: An economic model is currently being developed with the objective of estimating the cost effectiveness of the different methods of induction.
Main outcome measure: Cost per Quality Adjusted Life Year (QALY) gained for each method of induction. We will report incremental cost-effectiveness ratios and expected net benefit. The outcomes of the analysis will be plotted on the cost-effectiveness plane and cost-effectiveness acceptability curves will be constructed.
Design:
A decision tree analysis incorporating data from the systematic review and NMA, hospital costs, and utilities to quantify health-related quality of life. The expected clinical outcomes and costs in a hypothetical cohort of patients who experience the consequences of each induction strategy will be characterized.
An outline of the decision tree for each arm/method of induction is shown in Figure 6 . Figure 2 shows the results from the network meta-analysis (log-odds ratios) of the caesarean section outcome relative to the reference treatment placebo. 5 regimens resulted in significant reduction in caesarean section, namely vaginal PGE2 (gel), vaginal misoprostol tablet <50μg and ≥50μg, oral misoprostol tablet ≥ 50μg, and titrated (low dose) oral misoprostol solution. [3]
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Compared with placebo, odds of caesarean section were lowest for titrated oral misoprostol solution (<50μg) (OR 0.65; 95% CrI 0.49, 0.84).
Figure 5 (rankograms) shows the distribution of probabilities of each of the 12 prostaglandin treatments being ranked at each of the possible 12 positions, where position 1 means the treatment is ranked the highest. The probability that titrated oral misoprostol solution was the safest treatment in terms of risk of caesarean section was 67%. 
No vaginal delivery within 24 hours
The complete network of eligible comparisons between treatments for no vaginal delivery within 24 hours is shown in Figure 3 . 94 trials were available for inclusion. Figure 4 shows that there is strong evidence that all prostaglandins increase the odds of achieving a vaginal birth within 24 hours when compared with placebo. [3]
[13] Relative to placebo, the odds of failing to achieve a vaginal delivery were lowest for vaginal misoprostol (≥ 50μg) (OR 0.06; 95% CrI 0.02, 0.12).
Vaginal misoprostol (≥ 50μg) had the highest probability of being the most effective treatment for achieving vaginal birth; 53% ( Figure 5 ).
The results from the pairwise analysis were consistent with the Network Meta-Analysis
Neonatal Mortality, Maternal Mortality and Hyperstimulation
Maternal and neonatal mortality and serious morbidity were too rarely reported to carry out meaningful analysis and unresolved inconsistency was observed for the hyperstimulation outcome. Robust NMA estimates could therefore not be reported for these outcomes.
Utility Data
Due to a lack of data on maternal and neonatal health outcomes following induction of labour in the literature, we plan to elicit estimates of these from a group of experts using the Visual Analogue Scale. This consists of a continuous scale going from the worst health state imaginable to the best. Respondents are asked to place a mark on the line to indicate how good or bad they perceive each particular health state to be. These estimates will be used in the costeffectiveness analysis.
Cost Data
The methods of induction compared in this analysis have varying costs. The following are the costs per induction taken from the British National Formulary:
However, in order to determine the most cost-effective treatment from the perspective of the NHS and Personal Social Services, the cost of mode of delivery and adverse events must also be taken into account. Data on costs will be taken from NHS reference costs, ensuring that the results are generalizable to other settings. All costs will be expressed in UK pounds sterling. 
